# Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Source: https://onco.cc/trials/nct04068103/  
OnCo record `nct04068103` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of capecitabine, fluorouracil (5-FU), fOLFOX (5-FU, leucovorin, oxaliplatin) and leucovorin (folinic acid) in colorectal cancer, run by NRG Oncology, active but no longer recruiting.

## Summary

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery is a phase 2/3, randomised interventional study registered as NCT04068103 by NRG Oncology, with a registry enrolment figure of 635 participants, started 2019-12-16 and due to reach its primary completion in 2023-06-30. Interventions recorded: Capecitabine; Fluorouracil; Leucovorin; Leucovorin Calcium; Oxaliplatin; Patient Observation. Conditions listed: Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v8. Primary outcome: Clearance of Circulating Tumor Deoxyribonucleic Acid (ctDNA) (to Undetectable Levels) for the "Baseline ctDNA Detected" Patient Subset (Phase II); Recurrence-free Survival (RFS) the "Baseline ctDNA Detected" Patient Subset (Phase III). Colorectal eligibility wording from the registry: "* Histologically/pathologically confirmed stage IIA adenocarcinoma of the colon (T3, N0, M0) with at least 12 lymph nodes examined at the time of surgical resection". Sites: Canada, Puerto Rico, United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT04068103
- Phase: 2/3
- Setting: Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
- Sponsor: NRG Oncology
- Enrolled: 635

## Sources

- ClinicalTrials.gov NCT04068103: https://clinicaltrials.gov/study/NCT04068103

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/)
- companies: [NRG Oncology](https://onco.cc/companies/nrg-oncology/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04068103.json